Insider Cluster (2 insiders) ·Filed Sep 3, 2026

MAZE

Maze Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed28d 8h ago
Insider cluster: 2 insiders, $275K total
Actionable Insight • Neutral

Insider selling is too small to signal concern. Focus on Maze's pipeline catalysts and upcoming clinical data readouts for trading direction. Monitor for any material insider accumulation or larger sales.

DirectionNeutral
Confidencemedium
Horizonimmediate
Latest settled — T+5d ⚠ clustered
MAZE ▼ -4.91% at T+5d
NEUTRAL call ✗ call lost -4.91% · α vs SPY -3.76% · entry $25.87 → $24.60
Next anchor: T+20d due yesterday
Latest observation: T+17 +1.36% FF3 residual α
Entry anchored
Sep 2, 04:00 PM ET
via 1-min bar
T+1d
+1.31%
call +1.31% · α +1.70%
$26.21
settled 29d ago
T+5d
-4.91%
call -4.91% · α -3.76%
$24.60
settled 22d ago
T+20d
—
call — · α —
—
due yesterday
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Insider cluster at Maze Therapeutics shows CEO Jason Coloma and CSBO Atul Dandekar selling small amounts of stock over a 7-day window. Total disclosed sales of $275K (plus additional CEO sales of ~$907K per cross-filing context) represent less than 0.1% of the $1.5B market cap, making the activity trivial and non-informative. The CEO also exercised options (non-cash), consistent with routine portfolio management.

Key Financial Metrics

Direction
selling
Total Value
$275.0K
Insiders
2

Key Facts

  • CEO Jason Coloma sold 2.6K shares at $26.31 for $68K on 2026-09-01
  • CSBO Atul Dandekar sold 7.5K shares at $27.58 for $207K on 2026-08-28
  • Cross-filing context shows additional CEO sales of ~$907K on 2026-09-01, bringing total cluster to ~$1.1M
  • Total insider sales are <0.1% of Maze's $1.5B market cap
  • CEO also exercised 100K options at $0 (non-cash) on 2026-09-01

Financial Impact

Total insider selling of $275K (or ~$1.1M including cross-filing) is immaterial relative to $1.5B market cap

dilutioninsider ownership

Risk Factors

  • Insider selling may increase if stock continues to rise, but current levels are routine
  • Biotech sector volatility and binary pipeline events dominate price action

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MAZE-1788506445766
19 reports for MAZE
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+5▲ +5.16%Jun 3, 2026
Filters
Rows
Reports for MAZE — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 2/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 3/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 2, 2026
29d ago
144
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 1, 2026
4w ago
144
NEUTRAL ★ 3/10
$26.72 $24.82▼ −7.11%▼ −6.15%$26.69 (−0.12%)
Aug 17, 2026
6w ago
3
NEUTRAL ★ 1/10
$29.13 $30.42▲ +4.43%▲ +4.63%$26.69 (−8.38%)
Aug 11, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$27.53 $29.75▲ +8.06%▲ +8.51%$26.69 (−3.06%)
Aug 7, 2026
8w ago
Institutional Cluster
BULLISH ★ 5/10
$28.65 $27.18▼ −5.13%▼ −5.53%$26.69 (−6.85%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.81 $27.53▼ −1.01%▼ −1.36%$26.69 (−4.04%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$31.26 $32.42▲ +3.71%▲ +2.78%$26.69 (−14.63%)
Showing 10 of 19

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 4, 2026